ClinicalTrials.gg
RecruitingNCT06358898Updated Jul 10, 2025

Digital Mood-enhanced CBT-I to Improve Depressive Symptoms in Adolescents

An interventional study of Standard dCBT-I and Modified Mood enhanced CBT-I (M-dCBT-I) in Insomnia, Depression and Adolescent, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-07-10.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
343
Allocation
Randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 25 studies in Sleep Initiation and Maintenance Disorders by Chinese University of Hong Kong — 14 open to participants now, 14 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Chinese University of Hong Kong.

Planned enrollment
3rd of 25
343 · median 80
Started
2024
with 2 others
No phase
24 of 25
13 open now
Primary completion
2026-05
later than 3 of 13 live
Registered
15th of 25
by date

Among the 25 studies in Sleep Initiation and Maintenance Disorders by Chinese University of Hong Kong, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2024, is one of 24 with no phase, reaches primary completion later than 3 of the 13 other live ones, and was the 15th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

14 of the 25 studies in Sleep Initiation and Maintenance Disorders by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Where they have run

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Sleep Initiation and Maintenance Disorders by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

Emerging encouraging evidence showed that sleep focused treatment can simultaneously improve sleep and depression in adult with comorbid conditions. Although these favorable changes in depressed adults is encouraging, little is known in the potential efficacy of CBT-I in altering depression trajectory in adolescent population. This current study aims to compare the effect of digitally delivered, mood enhanced cognitive behavioral therapy for insomnia (M-dCBT-I) and standard digital cognitive behavioral therapy for insomnia (dCBT-I) in improving depressive symptoms in adolescents, and to examine the potential sustained treatment effect in mood outcomes following M-dCBT-I or dCBT-I treatment.

Read the detailed description

Adolescence is a critical transitional stage accompanied by the emergence of mental disorders, with major depressive disorder (MDD) being the most common mental disorder. The point prevalence of depression ranges from 3% to 18% across different studies. In addition, according to our previous studies, approximately 10% of adolescents experience insomnia disorders, and 36% have insomnia symptoms. Adolescent concurrently experiencing sleep and mood problems are typically at a higher risk of adverse health outcomes. This particular group is usually much more difficult to treat, with a poorer prognosis, suggesting that this group maybe in particular need for effective treatment.

There is accumulating evidence that adolescent sleep and mood problems can be treated successfully using cognitive behavioral therapy (CBT), which is one of the most extensively evaluated non-pharmacological approach for managing either depression or insomnia symptoms in adolescents. Cognitive behavioral therapy for depression (CBT-D) involves psychoeducation and addresses cognitive restructuring for unrealistic thinking contribute to depressed mood and behavioral strategies to increase pleasant activities. While cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment in managing adult insomnia, it has gained increasing empirical evidence in managing adolescent insomnia. The high comorbidity of insomnia and depression calls for the need for addressing both problems due to the fact that residual insomnia or residual depressive symptoms could further hasten a relapse to the other comorbid disorder. In addition, depression becomes more difficult to treat in the presence of insomnia. In fact, there has, however, been emerging encouraging evidence showing that sleep focused treatment can simultaneously improve sleep and depression in adult with comorbid conditions. Although these favorable changes in depressed adults is encouraging, little is known in the potential efficacy of CBT-I in altering depression trajectory in adolescent population.

This current study aims to compare the effect of digitally delivered, mood enhanced cognitive behavioral therapy for insomnia (M-dCBT-I) and standard digital cognitive behavioral therapy for insomnia (dCBT-I) in improving depressive symptoms in adolescents, and to examine the potential sustained treatment effect in mood outcomes following M-dCBT-I or dCBT-I treatment. Primary outcomes include the depressive symptoms as measured by PHQ-9, while secondary outcomes include clinician rated depression scale (HRSD), insomnia (ISI), sleep-related measures (Sleep diary variables, dysfunctional sleep belief), daytime sleepiness, anxiety (HADS), quality of life (Kidscreen-27). Outcome measurement will be conducted at baseline, postintervention, 6-month and 12-month follow up.

03

Conditions studied

  • Insomnia
  • Depression
  • Adolescent

Keywords

  • Insomnia
  • Depression
  • Adolescent
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese adolescent aged 12-18 years old
  2. presence of insomnia problems as defined by insomnia severity index ≥ 9 (locally validated cut off for detecting clinical insomnia in adolescents)
  3. presence of depressive problems as defined by Patient Health Questionnaire-9 (PHQ-9) using cut off of 10 for detecting clinical depression
  4. ability to read and understand Chinese
  5. possession of smartphone

Exclusion criteria

Exclusion Criteria:

  1. presence of prominent suicidality (suicide plans and suicide attempts) as determined by the Mini-International Neuropsychiatric Interview (MINI)
  2. a clinical diagnosis of psychosis, schizophrenia, bipolar disorders, or intellectual disability
  3. presence of other sleep disorders that significantly affect sleep continuity or sleep quality (e.g. restless leg symptoms or obstructive sleep apnea syndrome) as determined by validated Diagnostic Interview for Sleep Patterns and Disorders
  4. currently receiving psychological treatment for insomnia and/or pharmacological treatment for depression
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
343 participants (estimated)

Study arms

  • Active comparator
    Standard dCBT-I

    Treatment content for insomnia was structured and based on the well-established CBT elements for treating insomnia, with developmental adaptation and age-appropriate modification specific for adolescent population. For example, regularity of sleep wake pattern and circadian component will be further emphasized in this age group given the high prevalence of social jetlag resulting from the early school schedule and their natural development delay in circadian rhythm.

    Behavioral: Standard dCBT-I

  • Experimental
    Modified Mood enhanced CBT-I (M-dCBT-I)

    For mood-enhanced dCBT-I (M-dCBT-I), apart from including core CBT-I component, additional depression specific component including behavioral activation and problem solving. More specifically, cognitive restructuring techniques will cover both unhelpful belief relevant to both insomnia and depression. Psychoeducation will also cover both condition and vignette example will be included in the treatment.

    Behavioral: Modified Mood enhanced CBT-I (M-dCBT-I)

Interventions

  • BehavioralStandard dCBT-I

    This standard digital CBT-I intervention will cover (1) psycho-education about sleep, circadian and sleep hygiene education, (2) stimulus control, (3) sleep restriction, (4) relaxation techniques, (5) structured worry time, (6) cognitive restructuring (targeting sleep-related dysfunctional cognitions), and (7) relapse prevention. In order to have comparable dosage as modified CBT-I, the treatment will be dispersed to 8 modules (8-week) which is still in the range of standard CBT-I duration (usually last for 6-8weeks).

  • BehavioralModified Mood enhanced CBT-I (M-dCBT-I)

    Additional depression specific components will be added to the standard CBT-I, including behavioral activation and problem solving.

06

What researchers measure

Primary outcomes

  1. Depressive symptoms

    The severity of depressive symptoms as measured by Patient Health Questionnaire 9-item (PHQ-9): locally validated in adolescents and commonly used self-administered questionnaire to assess depressive symptoms and severity. Scores range from 0 to 27, with higher score indicate higher level of depression.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

Secondary outcomes

  1. Assessor-rated depressive symptomatology

    Hamilton Rating Scale for Depression (HRSD), a 17-item clinician-administered instrument, will be used to assess depressive symptomatology. Scores range from 0 to 52, with higher score indicate higher level of depression.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  2. Overall severity of depression symptoms

    Improvement of depression, in reference to the severity prior to the start of the treatment, will be rated using the Clinical Global Improvement Scale (CGI-I), on a scale of 1 (very much improved) to 7 (very much worse).

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  3. Severity of insomnia symptoms

    Severity of insomnia symptoms will be measured by Insomnia Severity Index (ISI). ISI is a self-report measure designed to assess the nature, severity and impact of insomnia, with a higher total score suggesting more severe insomnia symptoms. Scores range from 0 to 28.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  4. Sleep-wake pattern

    Prospective 7-day Sleep diary will be used to record sleep-wake pattern including sleep duration, wakeup time, bedtime and sleep latency.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  5. Sleep-related beliefs and cognitions

    Dysfunctional Beliefs and Attitudes about Sleep Scale (DBAS) will be used to measure faulty sleep-related beliefs and cognitions, which are cognitive aspects typically involved in the maintenance of insomnia. The total score is calculated from the average score of all the items on the scale and could range from 0 to 10.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  6. Daytime sleepiness

    8-item Pediatric Daytime Sleepiness Scale (PDSS) will be used to assess adolescents' daytime sleepiness in school children and adolescents. It is an 8-item inventory designed for use with school children and youths, with a higher score indicating greater sleepiness. Scores ranged from 0 to 32.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  7. Anxiety and depression symptoms

    Cantonese-Chinese version Hospital Anxiety and Depression Scale (HADS) will be used to assess anxiety and depression. It has been validated in the community-based sample of adolescents in Hong Kong. A higher total score of each subscale represents a greater severity of depression/anxiety. The total score for each subscale ranges from 0 to 21.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  8. Quality of life by KIDSCREEN-27

    KIDSCREEN-27 health questionnaire for children and young people will be used to measure quality of life. A grand total score can be calculated by summing up the five sub scores. In all cases, a higher score represents higher perceived well-being.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

Other outcomes

  1. Major life events and self-perceived stress

    Life Experience Survey (LES) will be used to measure major life events and self-perceived stress associated with these events that an individual experienced over the year.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  2. Chronotype

    Morningness-Eveningness Questionnaire (MEQ) will be used to measure the chronotype of the study participants. Individuals scored higher than 17 and lower than 12 were classified as morning-type and evening-type, respectively. Individuals scored between 12 and 17 were classified as intermediate-type. Scores range from 4 to 25.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

  3. Pubertal status

    Self-rated tanner stage will be used to measure pubertal status of the participants.

    Time frame: Baseline, Postintervention (8 weeks), 6-month follow up and 12-month follow up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2026, 25 months after the start.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 25 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2024
First posted
Apr 11, 2024
StartActual
Apr 20, 2024
Primary completionEst.
May 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06358898
Responsible party
CHAN NGAN YIN (Assistant Professor, Department of Psychiatry, Chinese University of Hong Kong) — Principal investigator
First posted
Apr 11, 2024
Start date
Apr 20, 2024
Primary completion
May 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 10, 2025

Study contacts

Rachel Ngan Yin Chan, PhD
Contact
rachel.chan@cuhk.edu.hk
39710548
Jucheng Yu, PhD
Contact
juchengyu@cuhk.edu.hk
39710548
Rachel Ngan Yin Chan, PhD
principal investigator · Department of Psychiatry, the Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion